Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure

被引：0

作者：

Gupta, A. ^{[1
]}

Laheru, D. ^{[1
]}

机构：

[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Med Oncol, Baltimore, MD USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1680P

引用

下载

页码：S921 / S921

页数：1

共 50 条

[31] A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Nie, C.
Lv, H.
Chen, B.
Xu, W.
Wang, J.
Wang, S.
Liu, Y.
He, Y.
Zhao, J.
Chen, X.
ANNALS OF ONCOLOGY, 2022, 33 : S1474 - S1474
[32] Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).
Koeller, Jim M.
Cockrum, Paul
Belanger, Bruce
Corvino, Frank A.
Surinach, Andy
Kim, George P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
Kim, G.
Cockrum, P.
Surinach, A.
Wang, S.
Lamarre, N.
ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
[34] A phase 1 study of liposomal irinotecan in patients with advanced breast cancer
Fan, Ying
Zhang, Qingyuan
Yan, Min
Qu, Xiujuan
Yin, Yongmei
Sun, Tao
Yang, Jin
Wang, Ying
Wang, Xu
Niu, Zhaofeng
Wang, Xinshuai
Sun, Sanyuan
Zhao, Weihong
Liu, Yanping
Miao, Niu
Zhao Xuemin
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] Survival predictors in pancreatic cancer patients on liposomal irinotecan plus fluorouracil/leucovorin: A multicenter observational study
Keum, J.
Lee, H. S.
Park, C. S.
Kim, J.
Jang, W.
Shin, K. I.
Kang, H.
Lee, S. H.
Jo, J. H.
Jang, S-I.
Chung, M. J.
Park, J. Y.
Park, S. W.
Cho, J. H.
Bang, S.
ANNALS OF ONCOLOGY, 2024, 35 : S143 - S143
[36] Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study
Keum, Jiyoung
Lee, Hee Seung
Park, Chan Su
Kim, Jeehoon
Jang, Wonjoon
Shin, Kyung In
Kang, Huapyong
Lee, Sang Hoon
Jo, Jung Hyun
Jang, Sung Ill
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Cho, Jae Hee
Bang, Seungmin
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[37] Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Chen, Li-Tzong
Macarulla, Teresa
Blanc, Jean-Frederic
Mirakhur, Beloo
de Jong, Floris A.
Belanger, Bruce
Bekaii-Saab, Tanios
Siveke, Jens T.
CANCERS, 2019, 11 (08)
[38] Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (US).
Kim, George P.
Cockrum, Paul
Surinach, Andy
Koeller, Jim M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
Kordes, Maximilian
Yu, Jingru
Malgerud, Oscar
Liljefors, Maria Gustafsson
Lohr, J-Matthias
CANCERS, 2019, 11 (09)
[40] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
Verbruggen, Lise
Verheggen, Lisa
Vanhoutte, Greetje
Loly, Catherine
Lybaert, Willem
Borbath, Ivan
Vergauwe, Philippe
Hendrickx, Koen
Debeuckelaere, Celine
de Haar-Holleman, Amy
Van Laethem, Jean-Luc
Peeters, Marc
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15

← 1 2 3 4 5 →